Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.

A user reported significant hair improvement using ginseng oil along with Minoxidil, finasteride, RU58841, and microneedling, leading them to cancel a hair transplant. Other users requested more details and proof.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The user is using a hair regrowth treatment plan that includes finasteride, microneedling, minoxidil foam, ketoconazole shampoo, and piroctone olamine shampoo. They are seeking advice on the effectiveness of their regimen and dosage of finasteride, and are curious about others' experiences with piroctone olamine.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.

The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

A user experienced side effects from finasteride and switched to using GHK-Cu for hairline improvement, noticing some positive changes after three months. They used a 2mg daily dose via subcutaneous injections and reported increased hair density and baby hairs, though results were not dramatic.

A user with PCOS experienced hair loss and found success using a triple dose of O.N.E Omega by Pure Encapsulations after discovering low Omega fatty acids. Biotin provided minimal improvement, but the Omega supplement significantly restored hair.

Vitamin D deficiency can hinder hair recovery, and addressing it may help with hair loss. Hair loss may result from various issues like excess DHT, vitamin deficiency, or scalp inflammation.

The user shared progress 128 days after a DHI hair transplant with 4261 grafts, using Finasteride, Minoxidil, Cutihance Men tablets, Omega-3, Vitamin D3 with K2, and one session of GFC PRP. They seek feedback on their progress compared to others' experiences.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.